TCW Group’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-11,829
| Closed | -$429K | – | 377 |
|
|
2023
Q3 | $429K | Sell |
11,829
-1,168
| -9% | -$41.5K | 0.01% | 284 |
|
|
2023
Q2 | $463K | Buy |
+12,997
| New | +$466K | 0.01% | 292 |
|
|
2021
Q1 | – | Sell |
-8,684
| Closed | -$400K | – | 342 |
|
|
2020
Q4 | $400K | Sell |
8,684
-770
| -8% | -$35.4K | ﹤0.01% | 320 |
|
|
2020
Q3 | $445K | Buy |
9,454
+955
| +11% | +$47.8K | ﹤0.01% | 303 |
|
|
2020
Q2 | $433K | Sell |
8,499
-1,530
| -15% | -$78.5K | 0.01% | 276 |
|
|
2020
Q1 | $475K | Sell |
10,029
-602
| -6% | -$32.1K | 0.01% | 277 |
|
|
2019
Q4 | $624K | Sell |
10,631
-1,440
| -12% | -$80.1K | 0.01% | 259 |
|
|
2019
Q3 | $644K | Sell |
12,071
-2,000
| -14% | -$103K | 0.01% | 255 |
|
|
2019
Q2 | $704K | Buy |
14,071
+34
| +0.2% | +$1.71K | 0.01% | 264 |
|
|
2019
Q1 | $733K | Sell |
14,037
-3,200
| -19% | -$160K | 0.01% | 262 |
|
|
2018
Q4 | $823K | Sell |
17,237
-2,252
| -12% | -$111K | 0.01% | 266 |
|
|
2018
Q3 | $979K | Sell |
19,489
-26,108
| -57% | -$1.33M | 0.01% | 273 |
|
|
2018
Q2 | $2.3M | Buy |
45,597
+4,720
| +12% | +$238K | 0.02% | 215 |
|
|
2018
Q1 | $2M | Sell |
40,877
-14,884
| -27% | -$693K | 0.02% | 222 |
|
|
2017
Q4 | $2.47M | Sell |
55,761
-4,064
| -7% | -$188K | 0.02% | 211 |
|
|
2017
Q3 | $3.04M | Sell |
59,825
-392
| -0.7% | -$19.9K | 0.02% | 198 |
|
|
2017
Q2 | $3.25M | Sell |
60,217
-7,477
| -11% | -$399K | 0.03% | 204 |
|
|
2017
Q1 | $3.57M | Sell |
67,694
-4,911
| -7% | -$249K | 0.03% | 189 |
|
|
2016
Q4 | $3.5M | Buy |
72,605
+1,316
| +2% | +$65K | 0.03% | 255 |
|
|
2016
Q3 | $3.84M | Buy |
71,289
+4,916
| +7% | +$270K | 0.03% | 215 |
|
|
2016
Q2 | $3.6M | Sell |
66,373
-8,568
| -11% | -$451K | 0.03% | 220 |
|
|
2016
Q1 | $3.8M | Sell |
74,941
-6,445
| -8% | -$321K | 0.03% | 215 |
|
|
2015
Q4 | $4.11M | Buy |
81,386
+47,046
| +137% | +$2.4M | 0.03% | 213 |
|
|
2015
Q3 | $1.65M | Sell |
34,340
-9,056
| -21% | -$471K | 0.01% | 400 |
|
|
2015
Q2 | $2.26M | Buy |
43,396
+1,651
| +4% | +$93K | 0.01% | 371 |
|
|
2015
Q1 | $2.41M | Sell |
41,745
-19,843
| -32% | -$1.14M | 0.01% | 583 |
|
|
2014
Q4 | $3.29M | Buy |
61,588
+13,072
| +27% | +$731K | 0.01% | 500 |
|
|
2014
Q3 | $2.79M | Buy |
48,516
+1,096
| +2% | +$67.2K | 0.01% | 615 |
|
|
2014
Q2 | $3.17M | Buy |
47,420
+13,500
| +40% | +$914K | 0.01% | 603 |
|
|
2014
Q1 | $2.27M | Sell |
33,920
-24,096
| -42% | -$1.63M | 0.01% | 650 |
|
|
2013
Q4 | $3.87M | Buy |
58,016
+30,948
| +114% | +$2.01M | 0.02% | 554 |
|
|
2013
Q3 | $1.7M | Hold |
27,068
| – | – | 0.01% | 681 |
|
|
2013
Q2 | $1.69M | Buy |
+27,068
| New | +$1.72M | 0.01% | 655 |
|
Other funds holding GSK
JEST
TCW Group's GSK Position: Q4 2023 in Review
TCW Group sold out of GSK (GSK) in Q4 2023, closing a stake of 11,829 shares — an estimated $429K sold.
TCW Group first reported a position in GSK in Q2 2013 and held it in 33 quarters. The position peaked at $4.11M in Q4 2015. 895 funds tracked by Wall St. Rank hold GSK as of Q4 2023.
- TCW Group reported no remaining GSK position as of Q4 2023 after selling out during the quarter.
- TCW Group sold 11,829 GSK shares in Q4 2023, an estimated $429K.
- TCW Group first reported a position in GSK in Q2 2013 and held it in 33 quarters.
- TCW Group's GSK position peaked at $4.11M in Q4 2015.
- 895 funds tracked by Wall St. Rank held GSK as of Q4 2023.
Based on TCW Group's 13F filing for Q4 2023, filed 9 Feb 2024.